CytoCore, Inc. Hires BVK to Promote New Initiatives in Women's Health.

CHICAGO -- CytoCore, Inc. (OTCBB:CYCR) announced the selection of BVK as its advertising and public relations agency of record. CytoCore, a biopharmaceutical research and medical device company focused on early detection and treatment of reproductive-tract cancers, will work with BVK on an imminent product launch. Together, the two companies will devise brand positioning and product pipelines to fit the needs of multiple audiences.

"CytoCore's rigorous selection process is expected to pay big dividends going forward," said CytoCore's President Dick Domanik. "It was vital that we identify an agency with strong credentials in both advertising and public relations, and substantial experience focusing on products and issues in women's health."

According to CytoCore CEO Bob McCullough, "BVK is made to order for the task at hand. BVK has a long history of helping newer companies target their key audiences and establish their brands in the marketplace. We are looking forward to a long and mutually rewarding relationship."

BVK has extensive expertise in healthcare marketing and communications. For more than 23 years, the agency has worked with healthcare providers, payors, biomedical, pharmaceutical and retail firms like Pfizer, Omron and Oklahoma University Medical Center, to launch new health related services and create brand identities. Its team of account strategists, researchers, PR practitioners, media experts, direct marketers, analytics and multicultural marketing experts offer CytoCore a full spectrum of branding expertise. BVK also is a champion of public health awareness, producing solid work for healthcare organizations by bringing to the forefront important national and regional social causes.

"Our work with Cytocore will allow us to combine our passion for women's health with our comprehensive knowledge of the healthcare industry," said Tricia Lewis, senior vice president/director, BVK Chicago. "This is an exciting time for Cytocore as we help them introduce systems that will make a major difference in women's healthcare."

About CytoCore Inc.

CytoCore is focused on women's health. The company develops and manufactures cost-effective medical devices and cancer screening systems which can be used in a laboratory or at the point-of-care to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

About BVK

One of North America's largest independent advertising agencies, BVK helps companies identify, engage, acquire and retain customers. With offices in Chicago, Milwaukee, Miami, Tampa, Kansas City, San Diego and Sacramento, BVK provides innovative integrated solutions including research, data analytics, strategic planning, advertising, customer relationship marketing, Hispanic marketing, public relations, promotions, media planning, sales promotion, directory advertising and digital asset management services. BVK's client list includes leading brands in a wide range of industries including healthcare, travel and tourism, recreation, academic and consumer/retail. For additional information, go to www.bvk.com.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.